Ann: CLARITY 2.0 COVID-19 Study Concludes Recruitment, page-24

A disappointing post from you Owl vs Fox.
Did no one ever explain to you that in a discussion attacking an individual personally is a sure sign you have lost the argument?.
This is not your or anyone else’s private site and the views of others are not “ BS” just because they don’t fit with your Investment strategy.

Fact: First interim analysis of ACTION 3 is planned for the first half of 2023. That’s 72 randomised patients that must have then been followed for 35 weeks and efficacy will be assessed on a surrogate marker of benefit, reductions in proteinuria.
Count back from 30 June 2023 , 35 weeks takes you back to end of October this year .So to achieve the goal 72 patients need to be randomised by then.
Fact: The Company hopes to fully fund the trial by Investors taking up options at 40c which is difficult to see happening before the interim analysis takes place.

There is nothing “ Pathetic” about pointing this out. If you , and other Investors, believe the Company is on track to achieve its own timetable then just ignore my post .

Have a nice weekend

EC